ArticleHemaSphere2025

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study.

Claudia Bellofiore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.